8-K: Plus Therapeutics Receives Nasdaq Delinquency Notice for Delayed Quarterly Report Filing

Plus Therapeutics, Inc. has received a notice from Nasdaq regarding its non-compliance with listing rules due to the delayed filing of its first-quarter 2025 financial report, though the notice has no immediate effect on its stock listing.

Summary

• Plus Therapeutics, Inc. (PSTV) received a notice from Nasdaq on May 21, 2025, indicating non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2025.
• Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (SEC).
• The Company has until July 21, 2025, to submit a plan to Nasdaq to regain compliance.
• If the plan is accepted, Nasdaq may grant an exception period of up to 180 calendar days from the filing's due date, or until November 17, 2025, to regain compliance.
• The notice has no immediate effect on the listing of Plus Therapeutics' securities on Nasdaq.
• Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat central nervous system cancers, including leptomeningeal metastases (LM) and recurrent glioblastoma (GBM).

Sentiment

Score: 3

Explanation: The sentiment is negative due to the non-compliance with Nasdaq listing rules and the delayed financial filing. While there's no immediate delisting and the company states it's working to resolve the issue, regulatory deficiencies introduce uncertainty and risk for investors.

Positives

• The Nasdaq notice has no immediate effect on the listing of the Company's securities, allowing time to address the deficiency.
• The Company is actively working to complete and file the Quarterly Report as promptly as possible and expects to return to a normal filing cadence.

Negatives

• Plus Therapeutics is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its Quarterly Report on Form 10-Q for Q1 2025.
• Failure to regain compliance within the specified timeframe could lead to delisting from Nasdaq.

Risks

• Uncertainty regarding Nasdaq's acceptance of the Company's compliance plan.
• The possibility that Nasdaq may not grant an extension or that the granted extension may not be sufficient.
• Potential inability to meet Nasdaq's requirements to regain compliance.
• Risk of additional delays in the filing of the Quarterly Report on Form 10-Q for the period ended March 31, 2025.
• The ultimate risk of delisting from Nasdaq if compliance is not regained.

Future Outlook

The Company is working diligently to complete and file its Quarterly Report on Form 10-Q as promptly as possible and expects to return to a normal filing cadence for the remainder of 2025.

Management Comments

• Marc H. Hedrick, M.D., President and Chief Executive Officer, signed the Form 8-K on behalf of Plus Therapeutics, Inc.
• The Company 'is working diligently to file the Quarterly Report as promptly as practical, and expects to return to a normal filing cadence for the remainder of 2025.'

Industry Context

This announcement pertains to a regulatory compliance issue, specifically a delayed financial filing, rather than a direct operational or clinical development within the biotechnology or pharmaceutical industry. While administrative, timely financial reporting is a fundamental expectation for publicly traded companies across all sectors, including the highly regulated pharmaceutical industry.

Stakeholder Impact

• Shareholders face increased uncertainty and potential risk of delisting if the Company fails to regain compliance.
• Regulatory bodies (Nasdaq, SEC) are monitoring the Company's adherence to listing and reporting requirements.

Next Steps

• Plus Therapeutics must submit a plan to Nasdaq to regain compliance by July 21, 2025.
• The Company plans to file its Quarterly Report on Form 10-Q for Q1 2025 as promptly as possible.

Key Dates

Recommendation

Keywords

Plus Therapeutics, PSTV, Nasdaq, SEC, Form 10-Q, Delayed Filing, Listing Rule 5250(c)(1), Compliance, Biotechnology, Pharmaceuticals, Radiotherapeutics, Glioblastoma, Leptomeningeal Metastases